T. Rowe Price Investment Management, Inc. Files Schedule 13G/A for Vaxcyte, Inc.
T. Rowe Price Investment Management, Inc. has filed an amended Schedule 13G/A regarding its ownership stake in Vaxcyte, Inc.
Stocks · News reference
Vaxcyte, Inc. announced its financial results for the third quarter ended September 30, 2026, and provided a business update.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
T. Rowe Price Investment Management, Inc. has filed an amended Schedule 13G/A regarding its ownership stake in Vaxcyte, Inc.
Analysts have slightly lowered the average 12-month price target for Vaxcyte, Inc. to $116.50, while maintaining a consensus “Buy” rating.
Cantor Fitzgerald analyst Carter Gould reiterates Vaxcyte (NASDAQ:PCVX) with a Overweight and announces $120 price target.
Stephen King slammed Trump’s incoming press secretary over her vaccine conspiracy theories and controversial posts.
Filed: 2026-10-09 AccNo: 0001193125-26-419174 Size: 2 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
A new NIH-backed initiative to speed up personalized cancer vaccine development sent stocks like MRNA, BNTX, and NVAX surging Friday.